Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

Autor: Vrede, S. W., Van Weelden, Willem Jan, Visser, N. C. M., Bulten, Johan, van der Putten, Louis J. M., van de Vijver, Koen, Santacana Espasa, Maria, Colàs Campàs, Laura, Gil-Moreno, Antonio, Moiola, Cristian P., Mancebo, Gemma, Krakstad, Camilla, Trovik, Jone, Haldorsen, Ingfrid S., Huvila, Jutta, Koskas, Martin, Weinberger, Vit, Bednarikova, M., Hausnerova, Jitka, van der Wurff, Anneke A. M., Matias-Guiu, Xavier, Amant, Frederic, ENITEC Consortium, Snijders, Marc P. L. M., Küsters-Vandevelde, Heidi V. N, Reijnen, Casper, Pijnenborg, Johanna M. A.

Publikováno v: Gynecologic Oncology, 161, 787-794
Gynecologic Oncology
Repositorio Abierto de la UdL
Universitad de Lleida
Scientia
GYNECOLOGIC ONCOLOGY
Gynecologic Oncology, 161, 3, pp. 787-794
Gynecologic oncology, 161(3), 787-794. Academic Press Inc.

Objective. Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMOESGO-ESTRO risk classification and ly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b055763b5e3d4f46151cd0216a6819
http://hdl.handle.net/2066/234186

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.

Autor: Vrede SW; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. Electronic address: stephanie.vrede@radboudumc.nl., van Weelden WJ; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands., Visser NCM; Department of Pathology, Stichting PAMM, Eindhoven, the Netherlands; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands., Bulten J; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands., van der Putten LJM; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands., van de Vijver K; Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Santacana M; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain., Colas E; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Gil-Moreno A; Gynecological Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain; Pathology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain., Moiola CP; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Mancebo G; Department of Obstetrics and Gynaecology, Hospital del Mar, PSMAR, Barcelona, Spain., Krakstad C; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Trovik J; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway., Haldorsen IS; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway; Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway., Huvila J; Department of Pathology, University of Turku, Turku, Finland., Koskas M; Department of Obstetrics and Gynaecology Department, Bichat-Claude Bernard Hospital, Paris, France., Weinberger V; Department of Obstetrics and Gynaecology, University Hospital in Brno and Masaryk University, Brno, Czech Republic., Bednarikova M; Department of Internal Medicine, Hematology and Oncology, University Hospital in Brno and Masaryk University, Brno, Czech Republic., Hausnerova J; Department of Pathology, University Hospital in Brno and Masaryk University, Brno, Czech Republic., van der Wurff AA; Department of Pathology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands., Matias-Guiu X; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain., Amant F; Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynaecologic Oncology, Netherlands Cancer Institute and Amsterdam Medical Centers, Amsterdam, the Netherlands., Snijders MPLM; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Küsters-Vandevelde HVN; Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Reijnen C; Department of Radiation Oncology, Radboud university medical center, Nijmegen, the Netherlands., Pijnenborg JMA; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2021 Jun; Vol. 161 (3), pp. 787-794. Date of Electronic Publication: 2021 Apr 12.